Allscripts (MDRX) Misses Q4 EPS by 1c, Offers Guidnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq futures slide as AI warnings rattle markets; Nvidia, other chip stocks retreat
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% amid Saudi pipeline outage after attack
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Jefferies Reiterates Buy on Allscripts (MDRX) Following 4Q
February 17, 2017 8:26 AM ESTJefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following 4Q earnings report. MDRX reported EPS of $0.14, which compares to $0.15 for consensus. Downside was driven by higher SG&A, partially offset by better revenue, a higher gross margin and... More
Allscripts (MDRX) PT Raised to $13 at Cantor Fitzgerald Following In-Line 4Q Results
February 17, 2017 7:22 AM ESTCantor Fitzgerald analyst Steven Halper reiterates Neutral rating and raises price target on Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) to $13 (from $12), suggesting shares remain fairly valued, as the company reported 2016 fourth quarter results in-line with estimates, while 2017 guidance was also in-line with... More
